TEL/AML1+ ACUTE LYMPHOBLASTIC LEUKEMIA IN THE GREEK PEDIATRIC POPULATION.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Subject Terms:
    • Abstract:
      INTRODUCTION: TEL/AMLI+ acute lymphoblastic leukemia (ALL) is considered to be a distinct nosological entity with excellent prognosis, but recent studies have indicated significant clinical heterogeneity. OBJECTIVE: In this study, we attempted to estimate the incidence and clinical features of TELIAMLI+ ALL for the first time in a representative cohort of Greek pediatric patients. METHODS: One hundred twenty children (<16 years old) diagnosed with ALL (107 of B-cell origin, 13 of T-cell origin) were screened for TEL/AMLI with interphase fluorescence in situ hybridization by using a commercial probe set. All patients were treated as either standard risk (SR) or high-risk (HR) cases according to a modified BFM-95 (Berlin-Frenkfurt-Munster) protocol. Follow-up ranged between 5 and 87 months (median: 45 months). RESULTS: Twenty-six patient (all of them will ALL of B-cell origin [24.3%1]) were found to be positive for TEL/AMLI. The presence of TEL/AMLI was significantly associated with younger age and lower white blood cell count at diagnosis but not with remission duration or overall survival rate. The number of children who relapsed (1 vs 7) or succumbed (1 vs 5) was comparable between the TEL/AMLI+ and TEL/AMLI- groups of children with ALL of B-cell origin. CONCLUSIONS: The incidence of TEL/AMLI in Greece seems comparable to that in other European and Mediterranean countries. As in most European studies, the independent prognostic value of TEL/AMLI is in doubt, because it is closely associated with other favorable factors. In this series, the modification of the therapeutic regimen (ie, omission of the SR arm) may be responsible for the similar outcome in TEL/AMLI+ and TEL/AMLI- cases, because it seems to lower the relapse risk for all children with ALL. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Pediatrics is the property of American Academy of Pediatrics and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)